Are acute subdural hematomas possible without head trauma?

Department of Neurosurgery, University of Turin, Turin, 'Department of Medicine, University of Salerno, Salerno, Italy

ABSTRACT
Acute subdural hematomas (ASDHs) are rarely reported in the literature. In general, it is due to head trauma, but if the traumatic event is very mild, it is inadequate to explain the ASDH occurrence. Risk factors for the development of spontaneous ASDH include hypertension, vascular abnormalities and deficit of coagulation. We present two cases of ASDH in patients with the coagulation deficit and review of the literature to understand the coagulation factors role and platelet role in the management of ASDHs.

Key words: Acute subdural hematomas, anticoagulant therapy, coagulation deficit

Introduction
Intracranial hemorrhage (ICH) accounts for approximately 10-15% of all cases of stroke, and it is associated with a high mortality rate.[1]

Mild traumatic brain injury (TBI) often occurs in elderly patients, many of whom are treated with anticoagulants, which are known to increase the risk of bleeding events.[2,3]

Oral anticoagulation therapy (OAT) is associated with a high risk of ICH, even after minor head trauma.[2,4-8] As a result, TBI patients with coagulopathy are included in a high-risk group regardless of clinical presentation.[5,9-12]

The European Federation of Neurological Societies recommends that patients with a Glasgow coma scale (GCS) of 15 after mild TBI who are over 60 years of age or who are on anticoagulation, need to be admitted to the hospital for 24-h observation.

Posttraumatic ICHs, including epidural hematoma, subdural hematoma (SDH), subarachnoid hemorrhage, intracerebral hemorrhage, and intraventricular hemorrhage, are usually seen in the initial computed tomography (CT) scan.

Acute subdural hematomas are rarely reported in the literature. They are frequently due to injury at cerebral bridging veins secondary to head trauma.[13] ASDHs generally begin to be symptomatic within 72 h and usually occur in young adults.

Spontaneous ASDH is an unusual event, but it is a serious condition. The reported incidences of spontaneous ASDHs relative to total ASDHs have ranged from 2 to 6.7%.[14-16]

Risk factors for the development of these hematomas include conditions such as hypertension, vascular abnormalities (such as aneurysm or arteriovenous malformation), or consumption of anticoagulant.[17]

Pharmacologic therapy linked with the development of spontaneous ASDH includes especially aspirin,[14,18] heparin,[14] and warfarin.[14,19-21]

Other reports of spontaneous ASDH mention risk factors such as coagulopathies related to coagulation factor deficiencies.[13,22,23] Mortality rate has been reported to be between 60% and 76.5%.[24,25]

Oral anticoagulation therapy increase the risk of SDH 4-to 15-fold.[26] The rate of oral anticoagulant (OAC)-associated SDH is related to the intensity of anticoagulation,[13] advanced patient age,[13] and perhaps cerebral atrophy.

The absolute rate of SDH can be estimated as approximately 0.2%/y in elderly patients given Oral anticoagulant (OAC) (international normalised ratio [INR] =3).
Infusion of prothrombin complex concentrate appeared to reverse the coagulopathy more rapidly than fresh frozen plasma and was associated with improved outcome in one small study.[27]

Early surgical intervention is generally imperative for hematomas with significant mass effect.

The survival rate for surgery within 4 h of acute onset compared with surgery after 4 h is 50-0%, respectively.[25] Other favorable variables include a high GCS score upon admission, appropriate pupillary reactivity, and young age.[25]

We present two cases of ASDH in patients with the coagulation deficit:
- Female patient with a history of alcoholic cirrhosis
- Male patient with a history of cardiac surgery in OAC.

The female patient, aged 59, arrived in an emergency room of our hospital at 9.30 a.m.

On admission to the hospital, the patient presented loss of consciousness, isocoria, midriasis and appropriate pupillary reactivity, decerebration extension at pain response, GCS 5 (E1, V1, M3).

Patient’s husband referred a mild TBI after fall at 11.30 p.m. of the day before, history of alcoholic cirrhosis, HBV- and HCV-, with esophageal varix (Grade I), severe platelet deficiency in pancytopenia.

In an emergency room, the anesthesiologist stabilized the patient.

Patient underwent the neuroimaging examination. CT scan showed acute subdural hematoma (ASDH) on left cerebral hemisphere with important midline structure shift, edema and indirect signs of ischemia [Figure 1]. The patient was diagnosed with ASDH.

After diagnosis patient was treated with a liquid infusion, Vitamin K, Voluven and proton pump inhibitor drugs before neurosurgical operation.

Decompressive pterional craniotomy was performed, and SDH was removed [Figure 2]. During the operation occurred hematemesis and melena. These events required hemotransfusion and endoscopic hemostasis of esophageal gastric bleeding.

She was conducted in the resuscitation room, and she died 2 days later for cardiac arrest.

A male patient, 58-year-old, arrived in an emergency room of our hospital complaining an increasing headache, dizziness and vomiting.

On admission to the hospital, he referred a history of cardiac surgery for mitral valve replacement in 2008 and medical therapy with coumadin - 5 mg and cordarone - 20 mg. He denied recent trauma. At neurological examination he was disoriented, confused, presented isocoria and absence of focal deficits. Patient underwent to neuroimaging examination. CT scan showed bilateral ASDH in fronto-temporo-parietal region more thickness in the left hemisphere, compressive effect on sovratentorial ventricular system and edema [Figure 3].

Coagulation parameters showed: INR = 2.98, aPtt = 51.3 s., derivated fibrinogen = 491 mg/dl, platelet = 116000/mm³.

Neurosurgical operation was delayed for preservation of consciousness state and presence of coagulative deficiency. The patient was treated with physiology and the electrolytic solution, Fenobarbital, Amiodarone and LMWE to replace OAT and adjust coagulative abset.

The day after INR was 2.79, aPtt = 49.6 s., fibrinogen = 579 mg/dl, platelet = 117000/mm³.

![Figure 1: Computed tomography scan shows acute subdural hematoma on left cerebral hemisphere with important midline structure shift, edema and indirect signs of ischemia](image1)

![Figure 2: Computed tomography scan of the brain after surgery](image2)
In the fourth hospitalization day his coagulation parameters were INR = 1.40, activated partial thromboplastin time (aPTT) = 34.4 s., fibrinogen = 663 mg/dl, platelet = 114000/mm$^3$. Because of consciousness falling, he retried a CT scan that showed an increase of the hematoma. For these reasons he was immediately treated with a neurosurgical operation.

**Methodology**

We report two cases of ASDH in uncoagulated patients:  
• Female patient, 59-year-old, history of cirrhosis  
• Male patient, 58-year-old, history of mitral valve replacement.

A literature search using PubMed MEDLINE database has been performed. The search terms “nontraumatic ASDH,” “spontaneous ASDH,” were combined with the following terms: “Platelet deficit,” “coagulation deficit.”

**Discussion**

In this review of the literature, we compared the incidence of platelet deficiency with dysfunction of coagulation factors in ASDHs.

All conditions resulting in a low platelet count can predispose a patient to ICH. Thrombocytopenia has multiple causes, and one common classification scheme is as follows:

- Decreased platelet production, as seen in certain congenital disorders and cases of bone marrow damage (due to radiation, drugs)
- Increased platelet destruction
- Abnormal sequestration, usually in the spleen, as in cirrhosis
- Multiple causes, as commonly seen in alcoholics.

Intracranial hemorrhage cases induced by thrombocytopenia have been linked to use of certain drugs, as well as to uremia, alcohol use, and liver transplants.

A large number of abnormalities of hemostasis were demonstrated in alcoholics patients.
abciximab,[35] as well as aspirin combined with extended-release dipyridamole.[38] Clopidogrel, abciximab, and dipyridamole all act as glycoprotein IIb/IIIa inhibitors in slightly different ways and have different indications [Table 1].

In a small number of studies, the authors have examined the risk of ICH in patients receiving these newer antiplatelet agents.

The most comprehensive data are derived from a meta-analysis conducted by Memon et al.,[37] in which the authors evaluated 14 randomized trials of intravenous platelet glycoprotein IIb/IIIa receptor inhibitors. The results of the aforementioned metaanalysis, while suggesting that intravenous glycoprotein IIb/IIIa inhibitors did not increase the risk of ICH in anticoagulant-treated patients, failed to provide information on the incidence of hemorrhagic stroke in patients receiving oral formulations of the medications alone. The authors also compared glycoprotein IIb/IIIa inhibitors with a more commonly used antiplatelet agent: Aspirin.

Analysis of current data suggests that the newer antiplatelet agents discussed thus seem to be associated with an ICH risk profile similar to that of aspirin.

Warfarin, heparin, and enoxaparin are currently the most commonly used anticoagulants.

Warfarin is an OAC that interferes with vitamin K metabolism in the liver and results in the synthesis of nonfunctional coagulation factors II, VII, IX, and X, as well as proteins C and S.

Warfarin thus prolongs the PT and is monitored by assessing a standardized form of this test known as the INR.

Heparin, on the other hand, is a parenterally administered anticoagulant agent that acts by potentiating the action of both antithrombin III and tissue factor pathway inhibitor (TFPI), thus prolonging the PTT.[38]

Enoxaparin is the most commonly used member of a relatively new class of anticoagulants known as low molecular weight heparins. It is obtained by alkaline degradation of heparin benzyl ester and is approximately one third the molecular size of standard heparin. The mechanism of action of enoxaparin is similar to that of heparin, although enoxaparin has a longer half-life (4.5 compared with 1.1 h) and does not require PTT monitoring.[39,40]

Anticoagulation-related bleeding is clinically similar for each of the aforementioned drugs and accounts for 10-20% of all ICHs in different series.[41-43] Furthermore, ICH is the most dreaded and least treatable complication of anticoagulation therapy.[44]

Aspirin appears to double the risk for ICH, regardless of the dose.[45] The combination of aspirin with warfarin probably increases the risk for ICH over similar intensities of anticoagulation without aspirin (pooled data from four randomized trials of OACs show 15 ICHs with aspirin 100-1000 mg/d versus 7 without aspirin).[31]

In the second Stroke Prevention in Atrial Fibrillation study, investigators showed that the occurrence of ICH actually negated the reduction in ischemic stroke among older hypertensive patients receiving warfarin.[46]

Approximately, 70% of ICH episodes associated with anticoagulation consist of intraparenchymal (cerebral) hemorrhage, whereas most of the remainder are SDHs.[3]

### Table 1: Anticoagulation/Antiplatelet Therapy

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanism of action</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>Inhibitor of cyclooxygenase</td>
<td>Platelet</td>
</tr>
<tr>
<td>Clopidogrel, abciximab, dipyridamole</td>
<td>Inhibitor of glycoprotein IIb/IIa</td>
<td>Platelet</td>
</tr>
<tr>
<td>Warfarin</td>
<td>Vitamine K liver metabolism</td>
<td>Coagulation factors II, VII, IX and X</td>
</tr>
<tr>
<td>Heparin</td>
<td>Potentiation of antithrombin III and TFPI</td>
<td>Antithrombin III inhibit thrombin, coagulation factor IX, X, XI, XII and kallikrein. TFPI inhibit trombin, coagulation factor VII, X</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>Potentiation of antithrombin III and TFPI</td>
<td>Antithrombin III inhibit thrombin, coagulation factor IX, X, XI, XII and kallikrein. TFPI inhibit trombin, coagulation factor VII, X</td>
</tr>
</tbody>
</table>

TFPI — Tissue factor pathway inhibitor

Enoxaparin is the most commonly used member of a relatively new class of anticoagulants known as low molecular weight heparins. It is obtained by alkaline degradation of heparin benzyl ester and is approximately one third the molecular size of standard heparin. The mechanism of action of enoxaparin is similar to that of heparin, although enoxaparin has a longer half-life (4.5 compared with 1.1 h) and does not require PTT monitoring.[39,40]

Anticoagulation-related bleeding is clinically similar for each of the aforementioned drugs and accounts for 10-20% of all ICHs in different series.[41-43] Furthermore, ICH is the most dreaded and least treatable complication of anticoagulation therapy.[44]

Aspirin appears to double the risk for ICH, regardless of the dose.[45] The combination of aspirin with warfarin probably increases the risk for ICH over similar intensities of anticoagulation without aspirin (pooled data from four randomized trials of OACs show 15 ICHs with aspirin 100-1000 mg/d versus 7 without aspirin).[31]

In the second Stroke Prevention in Atrial Fibrillation study, investigators showed that the occurrence of ICH actually negated the reduction in ischemic stroke among older hypertensive patients receiving warfarin.[46]

Approximately, 70% of ICH episodes associated with anticoagulation consist of intraparenchymal (cerebral) hemorrhage, whereas most of the remainder are SDHs.[3]

### Conclusion

Coagulation and/or bleeding disorders account only for a small but significant risk factor associated with ICH. Blood coagulation and platelet-mediated hemostasis are the two important defense mechanisms against bleeding.

Anticoagulant mechanisms ensure careful control of coagulation and under normal conditions, prevail over the procoagulant forces. In the CNS, however, an imbalance between pro- and anticoagulant systems due to inherited or acquired factors may result in bleeding or thrombotic diseases.

Spontaneous ASDH is a nosological entity rare but extremely serious. In our view it would be appropriate to perform a series of study to understand the most appropriate medical therapy in the management of disease: Is more useful adjust platelet deficiency, coagulation factors disorder, or both?

### References

4. Fabbri A, Vandelli A, Servadei F, Marchesini G. Coagulopathy and


Source of Support: Nil, Conflict of Interest: None declared.